Actinium-225 Production Expansion Will Capitalize On Next-Generation Cancer Treatments

AN
AnalystConsensusTarget
Consensus Narrative from 3 Analysts
Published
23 Mar 25
Updated
24 Jul 25
AnalystConsensusTarget's Fair Value
€16.67
28.8% undervalued intrinsic discount
24 Jul
€11.86
Loading
1Y
-2.5%
7D
-2.8%

Author's Valuation

€16.7

28.8% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Decreased 5.09%

Shared on24 Apr 25
Fair value Decreased 3.41%

AnalystConsensusTarget has decreased revenue growth from 13.1% to 9.3%, decreased profit margin from 9.3% to 6.4% and increased future PE multiple from 9.9x to 15.5x.

Shared on17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Increased 9.08%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Increased 3.14%

Shared on26 Mar 25
Fair value Decreased 7.66%

AnalystConsensusTarget has increased revenue growth from 6.7% to 7.5%.